Navigation Links
FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen
Date:2/1/2012

Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339; toll free at 1-877-273-3713 or via email at clinicaltrials@shc.org.

About the Virginia G. Piper Cancer Center at Scottsdale Healthcare
The Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Ariz. offers comprehensive cancer treatment and research through Phase I clinical trials, diagnosis, prevention and support services in collaboration with leading scientific researchers and community oncologists. Scottsdale Healthcare is the nonprofit parent organization of the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute, Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital. For more information, visit www.shc.org.

About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.


'/>"/>
SOURCE Scottsdale Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Monday, December 8, 2014 at 9:00 a.m. Eastern Time to ... th American Society of Hematology Annual Meeting and Exposition.  ... by dialing 877-443-5662 or access the webcast at www.isispharm.com ... time at the same address. ABOUT ISIS ...
(Date:11/18/2014)... 18, 2014  Renova Therapeutics, a biopharmaceutical company ... and other chronic diseases, announced that Daniel ... The company also completed its third round of ... board member brings decades of life science experience ... executive with more than 30 years of experience ...
(Date:11/17/2014)... STAAR Surgical Company (NASDAQ: STAA ... lenses and delivery systems for the eye, today announced ... Medical Technology & Diagnostics Forum in New ... Thursday, November 20 at 12:30 p.m. PT/3:30 p.m. ET. ... of the Company,s current business trends, financial results, and ...
Breaking Medicine Technology:Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 3Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round 2Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round 3STAAR Surgical To Present At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum 2
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. 17, ... to extremely low levels with a combination drug appears ... patients with clogged arteries, a new study found. ... Vytorin, a drug that combines a cholesterol-lowering statin called ... investigator Dr. Christopher Cannon, a cardiologist at Brigham and ...
(Date:11/18/2014)... News) -- Women who started smoking at a young ... menstrual pain, a new study suggests. About 29 ... has been suspected as a risk factor for severe ... of the new study said. The researchers analyzed ... study of women,s health in Australia. About 14 percent ...
(Date:11/18/2014)... Hills, CA (PRWEB) November 18, 2014 ... and workflow solutions, announced today their Gold sponsorship of ... November 19th through Friday, November 21st at the Fargo, ... event offering targeted Microsoft Dynamics GP training sessions and ... the Microsoft campus is an excellent way for users ...
(Date:11/18/2014)... Recently, Wigsbuy has introduced its newest collection of ... greatly discounted prices now, up to 85% off. , Wigsbuy ... products, offering many real and synthetic hair products. In order ... uses high quality materials to make its hair wigs, which ... , “We are offering a full line of human ...
(Date:11/18/2014)... Thompson HealthDay Reporter , MONDAY, ... patients can safely take aspirin combined with a blood-thinning medication, ... a patient,s risk of early death, according to a new ... Heart Association in Chicago. The report was also published online ... data from more than a dozen clinical trials revealed no ...
Breaking Medicine News(10 mins):Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 3Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3
... Sudden cardiac,arrest is a leading cause of death ... condition, it is imperative that every school develop ... they need to respond,effectively to children and adults ... perform CPR and use an automated external defibrillator,(AED) ...
... Jones addressed the issue of health disparities during a,Ways ... part are,as follows., "Mr. Chairman, I am appreciative ... disparities as we continue to move forward with,health reform ... not just to my district, but to,districts across the ...
... on the Impact of ... Technology in Healthcare, PLANO, Texas, June 10 ... President, International Healthcare Guest: ... Humana, Perot Systems continues its series of ...
... drug approved for osteoporosis prevention and treatment has provided ... a breast cancer preventative for certain cancers. Women ... develop invasive, estrogen-receptor (ER) positive breast cancer compared with ... results of the randomized controlled trial will be published ...
... , , TUESDAY, June 10 (HealthDay News) -- Regardless of the ... women, and smoking increases any adult,s risk of death just ... according to new risk of death charts. , The charts, ... the Journal of the National Cancer Institute show ...
... Maine, June 10 Sen. Olympia Snowe,(R-ME), member ... Medicare,bill -- S.3101 -- that includes pharmacy-related provisions ... drug claims and delay the,implementation of Medicaid reimbursement ... RPh, owner of Waltz Pharmacy Inc. in,Camden, ME ...
Cached Medicine News:Health News:Statement of Robert O'Connor, M.D., M.P.H. Chair, American Heart Association, Emergency Cardiovascular Committee, on U.S. House of Representatives Passage of the Josh Miller HEARTS Act 2Health News:Tubbs Jones Addresses Health Disparities Issue During Hearing 2Health News:Healthcare Tech and the World: A New Perspective on Innovation in Healthcare 2Health News:Healthcare Tech and the World: A New Perspective on Innovation in Healthcare 3Health News:Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women 2Health News:Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women 3Health News:Researchers Update Risk-of-Death Charts 2Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2
Shafts angled 8 mm from tip to bend with smooth jaws. Flat, cross action handle with holes and dull finish....
... designed with thinner, long jaws to ... through a tunnel or clear corneal ... lens securely, but will not damage ... enough to allow the lens to ...
Titanium. Designed to easily fold the hydroview lens. Will also fold many styles of soft intraocular lenses. Unique cross-action design facilitates folding of the lens....
Angled 45 degree shafts. 7 mm from tip to bend with grooved 2 mm platform for grasping lens haptic. Serrated McPherson style handle with dull finish....
Medicine Products: